SR One by GSK

What is SR One by GSK?

SR One is a biotechnology venture capital firm with a focus on powering the arc of innovation from science to medicine.

As a corporate VC arm of GlaxoSmithKline (GSK), they are committed to partnering with founders and entrepreneurs to translate cutting-edge science into transformative medicine.

SR One's investment strategy encompasses a back-and-build approach, prioritizing investments in companies that showcase strong underlying fundamentals, clear development pathways, and innovative methods for addressing diseases. With their investment thesis rooted in a belief in reimagining today's science for tomorrow's medicines, they are equipped to support their portfolio companies both financially and strategically.

SR One maintains a significant presence across key biotechnology hubs, with their investing team located on the West Coast of the United States as well as in London, UK. This transatlantic footprint enables them to access high-quality science and opportunities from different geographies, ensuring a diverse and rich portfolio.

They are actively invested in fostering growth and providing business support to their portfolio companies by leveraging their geographic reach and regional expertise. This approach allows SR One to act as a strategic partner, staying close to real-time developments in the biotech sector, and mining opportunities as they emerge. SR One's engagement is characterized by their deep involvement in building enterprises with the potential to create a substantial impact on the healthcare industry.